Voztelecom is a technology company specialising in communications and cloud services for SMEs, which on 28 July decided to go public on the MAB, after carrying out an initial public offering. capital increase of €3M.
Its objective with the MAB listing is to finance the commercial expansion of its OIGAA 360° franchise network.
Since its launch at the end of 2014, the company already has five franchises (Barcelona, Cerdanyola del Vallès, Elche, Girona and Mataró), which generated 55% of new registrations in 2015, and plans to increase this network to more than 20 franchised service points throughout Spain.
With more than twelve years in the market, Voztelecom has experienced strong growth in recent years, exceeding nine million Euros in turnover in 2015. Since its birth in 2003, it has been leading the migration of the telephony and communications systems of its clients, towards IP in its first years of life, and a few years later towards the cloud.
Atrys Health, which provides diagnostic services and medical treatments that combine precision diagnostic techniques in pathology and molecular anatomy and online imaging, becomes the twelfth company to enter this market so far this year.
Before going public on Mab, the company previously closed a €4.5m share subscription offer, bringing its initial capitalisation to €16.5m.
Following this capital increase, 29% of the company's shares are controlled by Inveready, a private equity investment group.
The company closed 2015 with a turnover of €2.9M in Spain, up 163 % compared to 2014, and a net profit of €1.3M.
Masmovil The Mab-listed company bought Yoigo for €612m and Pepephone for €158m this summer.
With the purchase of Yoigo, Masmovil will be able to develop a convergent offer based on its own fixed and mobile networks to compete with the three operators providing convergent electronic communications services (fixed+mobile).
AB Biotics, has completed a €5M capital increase to accelerate its internationalisation plan and establish itself as a global leader in biotechnology and genetic research.
The financial director of AB Biotics, Alejandro García Moncayo, said that with this capital increase the company consolidates a technological stage and provides itself with the resources to maintain and accelerate an international commercialisation process initiated in 2012 "with very good expectations for the next two years", dedicating a large part of the funds to the expansion plan.
Other posts that may interest you
Clerhp structures exits the mab up 10.24%
TECNOQUARK goes public on the MAB to finance growth
If you are thinking about the go to MAB, get in touch with us. Abra-Invest has an expert team, who will advise you to make the process successful. Call us on + 34 946424142 or fill in the contact form.
EN 
ES